Bristol-Myers Squibb’s Opdivo fails to meet key endpoint in small cell lung cancer trial

Bristol-Myers Squibb’s cancer drug Opdivo (nivolumab) has failed to meet the primary endpoint in the Phase 3 CheckMate -331 trial, designed to assess its effectiveness ... Read More